Immunomodulatory Effects of Selenium on T-Cell-Mediated Responses in Thyroid Eye Disease
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Thyroid Eye Disease (TED) is an autoimmune orbital disorder driven by pathogenic T-cell subsets, including T-helper 1 (Th1) and follicular helper T (Tfh) cells, which sustain orbital inflammation and thyroid-stimulating immunoglobulin (TSI) production. Selenium supplementation has demonstrated clinical benefit in mild TED, yet its immunological mechanisms remain poorly defined.
Methods
A murine TED model was established in female BALB/c mice via TSHR plasmid immunisation. Animals maintained on a low-selenium diet (0.07 ppm) received sodium selenite supplementation at 0.2 mg/kg/day. Orbital pathology was assessed by immunohistochemistry, H&E and Masson’s Trichrome staining. T-cell subset abundance was quantified by flow cytometry, and serum T4, TRAb, and IL-21 levels were measured by ELISA. In vitro dose-response experiments examined the effects of selenium on Tfh cell viability, IL-21 production, apoptosis, and ferroptosis.
Results
Selenium supplementation reduced CD3⁺ T-cell orbital infiltration, collagen fibrosis, and serum T4 and TRAb levels in TSHR-immunised mice. Flow cytometry revealed significant reductions in Tfh and Th1 cell abundance, with Th17 cells unaffected. Serum IL-21 and B-cell abundance were also markedly reduced in vivo. In vitro, selenium exhibited a biphasic, dose-dependent effect on Tfh cells: low concentrations maintained viability and IL-21 production, while higher concentrations induced ferroptosis and apoptosis.
Conclusions
Selenium modulates pathogenic T-cell responses in TED, most prominently suppressing the Tfh compartment and attenuating the Tfh–B cell–autoantibody axis via ferroptosis and apoptosis. These findings suggest a mechanistic framework for the clinical benefit of selenium in mild TED and highlight the importance of dose selection within its narrow therapeutic window.
